{"id":"ivermectin-on-day-1","safety":{"commonSideEffects":[{"rate":null,"effect":"Pruritus"},{"rate":null,"effect":"Headache"},{"rate":null,"effect":"Dizziness"},{"rate":null,"effect":"Arthralgia/myalgia"},{"rate":null,"effect":"Mazzotti reaction (fever, lymphadenitis)"}]},"_chembl":{"chemblId":"CHEMBL6067487","moleculeType":"Unknown"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Ivermectin selectively targets invertebrate-specific ion channels, particularly glutamate-gated chloride channels found in nematodes and arthropods. By binding to these channels, it increases chloride conductance, leading to hyperpolarization of nerve and muscle cells, resulting in paralysis and death of the parasite. The drug has high selectivity for parasitic channels over mammalian GABA receptors due to structural differences.","oneSentence":"Ivermectin is a macrocyclic lactone that binds to glutamate-gated chloride channels in parasites, causing paralysis and death.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:17:31.265Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Onchocerciasis (river blindness)"},{"name":"Lymphatic filariasis"},{"name":"Strongyloidiasis"},{"name":"Scabies"},{"name":"Lice infestation"}]},"trialDetails":[{"nctId":"NCT05500326","phase":"PHASE2","title":"Ivermectin Therapy for Scabies Infection in Children Younger Than 5 Years of Age (ITCHY Study)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Murdoch Childrens Research Institute","startDate":"2025-06-24","conditions":"Scabies; Itch, Scabies","enrollment":120},{"nctId":"NCT07487805","phase":"PHASE2","title":"Ivermectin Combined With Immune Checkpoint Inhibition in Cancer (ICONIC)","status":"NOT_YET_RECRUITING","sponsor":"University of Florida","startDate":"2026-07","conditions":"Solid Tumor, Adult","enrollment":80},{"nctId":"NCT05041907","phase":"PHASE2","title":"Finding Treatments for COVID-19: A Trial of Antiviral Pharmacodynamics in Early Symptomatic COVID-19 (PLATCOV)","status":"RECRUITING","sponsor":"University of Oxford","startDate":"2021-09-30","conditions":"COVID-19","enrollment":3800},{"nctId":"NCT07286604","phase":"EARLY_PHASE1","title":"Ivermectin Repurposed for the Treatment of PKDL","status":"COMPLETED","sponsor":"International Centre for Diarrhoeal Disease Research, Bangladesh","startDate":"2022-03-02","conditions":"Post Kala Azar Dermal Leishmaniasis","enrollment":10},{"nctId":"NCT05318469","phase":"PHASE1, PHASE2","title":"Ivermectin in Combination With Balstilimab or Pembrolizumab in Patients With Metastatic Triple Negative Breast Cancer","status":"RECRUITING","sponsor":"Yuan Yuan","startDate":"2023-10-13","conditions":"Anatomic Stage IV Breast Cancer AJCC v8, Metastatic Triple-Negative Breast Carcinoma","enrollment":34},{"nctId":"NCT04885530","phase":"PHASE3","title":"ACTIV-6: COVID-19 Study of Repurposed Medications","status":"COMPLETED","sponsor":"Susanna Naggie, MD","startDate":"2021-06-08","conditions":"Covid19","enrollment":10956},{"nctId":"NCT06282315","phase":"PHASE3","title":"Real World Evaluation of an Albendazole-Ivermectin Coformulation Safety and Effectiveness","status":"RECRUITING","sponsor":"Insud Pharma","startDate":"2025-09-01","conditions":"Soil-Transmitted Helminths","enrollment":20000},{"nctId":"NCT06251739","phase":"EARLY_PHASE1","title":"Repurposing Ivermectin for PKDL Treatment","status":"COMPLETED","sponsor":"International Centre for Diarrhoeal Disease Research, Bangladesh","startDate":"2023-10-30","conditions":"Post-kala-azar Dermal Leishmaniasis","enrollment":30},{"nctId":"NCT06582043","phase":"NA","title":"Evaluation of the Efficacy and Tolerance of Two Cosmetic Products in Subjects With Rosacea","status":"COMPLETED","sponsor":"NAOS Argentina S.A.","startDate":"2024-05-16","conditions":"Rosacea, Redness, Telangiectasia","enrollment":70},{"nctId":"NCT06033352","phase":"PHASE2","title":"Potassium-titanyl Phosphate (KTP) Laser vs KTP Laser and Ivermectin Cream for Facial Rosacea","status":"COMPLETED","sponsor":"Insel Gruppe AG, University Hospital Bern","startDate":"2023-09-12","conditions":"Rosacea","enrollment":22},{"nctId":"NCT02735707","phase":"PHASE3","title":"Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community- Acquired Pneumonia","status":"RECRUITING","sponsor":"UMC Utrecht","startDate":"2016-04-11","conditions":"Community-acquired Pneumonia, Influenza, COVID-19","enrollment":20000},{"nctId":"NCT04510194","phase":"PHASE3","title":"COVID-OUT: Early Outpatient Treatment for SARS-CoV-2 Infection (COVID-19)","status":"COMPLETED","sponsor":"University of Minnesota","startDate":"2021-01-01","conditions":"Covid19, SARS-CoV Infection","enrollment":1323},{"nctId":"NCT06332872","phase":"PHASE4","title":"Comparison Effectiveness of Oral Ivermectin , 1% Permethrin Shampoo and 4% Dimeticone Liquid Gel in the Treatment of Pediculosis Capitis Among School Children in Chachoengsao Province, Thailand","status":"ACTIVE_NOT_RECRUITING","sponsor":"Phramongkutklao College of Medicine and Hospital","startDate":"2023-12-15","conditions":"Pediculus Capitis Infestation, Permethrin Adverse Reaction, Dimethicone Adverse Reaction","enrollment":117},{"nctId":"NCT05925140","phase":"PHASE1","title":"LUSZ Treatment Efficacy in Hospitalized COVID-19 Patients","status":"UNKNOWN","sponsor":"Lebanese University","startDate":"2020-03-28","conditions":"COVID-19, Hospitalized COVID-19 Patients","enrollment":1000},{"nctId":"NCT03605758","phase":"PHASE3","title":"Treatment of Strongyloides Infection","status":"TERMINATED","sponsor":"Albert Einstein College of Medicine","startDate":"2012-05","conditions":"Strongyloides Stercoralis Infection, Strongyloidiasis","enrollment":51},{"nctId":"NCT05946642","phase":"PHASE3","title":"Innovative Intermittent Preventive Treatment Approaches to Reduce Malaria Burden in School-age Children in Burkina Faso","status":"UNKNOWN","sponsor":"Malaria Consortium","startDate":"2023-07-15","conditions":"Malaria","enrollment":13000},{"nctId":"NCT05894538","phase":"PHASE3","title":"ACTIV-6: COVID-19 Study of Repurposed Medications - Arm D (Ivermectin 600)","status":"COMPLETED","sponsor":"Susanna Naggie, MD","startDate":"2022-02-16","conditions":"Covid19","enrollment":1459},{"nctId":"NCT05736861","phase":"PHASE3","title":"ACTIV-6: COVID-19 Study of Repurposed Medications - Arm A (Ivermectin 400)","status":"COMPLETED","sponsor":"Susanna Naggie, MD","startDate":"2021-06-08","conditions":"Covid19","enrollment":1800},{"nctId":"NCT05819983","phase":"PHASE4","title":"Ivermectin/ Permethrin for Scabies","status":"COMPLETED","sponsor":"Universitas Padjadjaran","startDate":"2023-01-25","conditions":"Scabies","enrollment":60},{"nctId":"NCT05477810","phase":"EARLY_PHASE1","title":"Bioequivalence of a Single-dose of 12 mg IVERMECTIN as Orally Disintegrating Mini Tablets Versus a Single-dose of 12 mg Regular IVERMECTIN Tablets in Healthy Adults Under Fasting Conditions","status":"COMPLETED","sponsor":"University Children's Hospital Basel","startDate":"2022-09-13","conditions":"Bioequivalence","enrollment":16},{"nctId":"NCT03570814","phase":"PHASE4","title":"Cluster RCT of Co-administration Azithromycin, Albendazole & Ivermectin","status":"COMPLETED","sponsor":"London School of Hygiene and Tropical Medicine","startDate":"2021-12-01","conditions":"Trachoma, Lymphatic Filariases","enrollment":13511},{"nctId":"NCT04447235","phase":"PHASE2","title":"Early Treatment With Ivermectin and LosarTAN for Cancer Patients With COVID-19 Infection","status":"TERMINATED","sponsor":"Instituto do Cancer do Estado de São Paulo","startDate":"2020-07-23","conditions":"Cancer, COVID, Coronavirus Infection","enrollment":77},{"nctId":"NCT05271968","phase":"NA","title":"Place of Hygiene in Scabies's Treatment in Populations in Precarious Situations","status":"UNKNOWN","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2022-04","conditions":"Scabies","enrollment":218},{"nctId":"NCT04703205","phase":"PHASE2","title":"Study in COvid-19 Patients With iveRmectin (CORVETTE-01)","status":"UNKNOWN","sponsor":"Kitasato University","startDate":"2020-09-16","conditions":"Covid19","enrollment":214},{"nctId":"NCT05198947","phase":"NA","title":"Better Disease Control by Multidrug Regimen in Scabies","status":"COMPLETED","sponsor":"B.P. Koirala Institute of Health Sciences","startDate":"2017-01","conditions":"Scabies","enrollment":212},{"nctId":"NCT04894721","phase":"PHASE2, PHASE3","title":"Prophylaxis for COVID-19: Ivermectin in Close Contacts of COVID-19 Cases (IVERNEX-TUC)","status":"COMPLETED","sponsor":"Ministry of Public Health, Argentina","startDate":"2021-06-01","conditions":"Covid19","enrollment":172},{"nctId":"NCT04635943","phase":"PHASE2","title":"Randomized Phase IIA Clinical Trial to Evaluate the Efficacy of Ivermectin to Obtain Negative PCR Results in Patients With Early Phase COVID-19","status":"COMPLETED","sponsor":"Universidad Peruana Cayetano Heredia","startDate":"2020-08-29","conditions":"Covid19, Coronavirus Infection, SARS-CoV Infection","enrollment":186},{"nctId":"NCT04729140","phase":"PHASE4","title":"An Outpatient Clinical Trial Using Ivermectin and Doxycycline in COVID-19 Positive Patients at High Risk to Prevent COVID-19 Related Hospitalization","status":"UNKNOWN","sponsor":"Max Health, Subsero Health","startDate":"2020-12-28","conditions":"Covid19","enrollment":150},{"nctId":"NCT04746365","phase":"PHASE4","title":"Ivermectin Role in Covid-19 Clinical Trial","status":"COMPLETED","sponsor":"Elaraby Hospital","startDate":"2020-12-06","conditions":"Covid19","enrollment":300},{"nctId":"NCT04435587","phase":"PHASE4","title":"Ivermectin vs Combined Hydroxychloroquine and Antiretroviral Drugs (ART) Among Asymptomatic COVID-19 Infection","status":"UNKNOWN","sponsor":"Mahidol University","startDate":"2020-07-13","conditions":"Asymptomatic Infections, SARS-CoV2 Infection","enrollment":80},{"nctId":"NCT03177993","phase":"NA","title":"Fiji Integrated Therapy (FIT) - Triple Therapy for Lymphatic Filariasis, Scabies and Soil Transmitted Helminths in Fiji","status":"COMPLETED","sponsor":"Washington University School of Medicine","startDate":"2017-07-13","conditions":"Lymphatic Filariases, Scabies, Impetigo","enrollment":4773},{"nctId":"NCT04425863","phase":"","title":"Ivermectin, Aspirin, Dexamethasone and Enoxaparin as Treatment of Covid 19","status":"COMPLETED","sponsor":"Eurnekian Public Hospital","startDate":"2020-05-01","conditions":"Severe Acute Respiratory Syndrome, Ventilation Pneumonitis","enrollment":167},{"nctId":"NCT04384458","phase":"NA","title":"Comparative Study of Hydroxychloroquine and Ivermectin in COVID-19 Prophylaxis","status":"UNKNOWN","sponsor":"Nucleo De Pesquisa E Desenvolvimento De Medicamentos Da Universidade Federal Do Ceara","startDate":"2020-07-20","conditions":"Coronavirus Infections","enrollment":400},{"nctId":"NCT04373824","phase":"NA","title":"Max Ivermectin- COVID 19 Study Versus Standard of Care Treatment for COVID 19 Cases. A Pilot Study","status":"UNKNOWN","sponsor":"Max Healthcare Insititute Limited","startDate":"2020-04-25","conditions":"COVID","enrollment":50},{"nctId":"NCT03301649","phase":"PHASE3","title":"Clinical Endpoint Study of Ivermectin 0.5% Lotion","status":"COMPLETED","sponsor":"Actavis Inc.","startDate":"2017-10-07","conditions":"Head Lice","enrollment":905},{"nctId":"NCT02775617","phase":"PHASE4","title":"Azithromycin - Ivermectin Mass Drug Administration for Skin Disease","status":"COMPLETED","sponsor":"London School of Hygiene and Tropical Medicine","startDate":"2016-07","conditions":"Scabies, Yaws, Impetigo","enrollment":1291},{"nctId":"NCT03676140","phase":"PHASE3","title":"Safety of Co-administration of IDA and Azithromycin for NTDs ( ComboNTDs )","status":"COMPLETED","sponsor":"Lihir Medical Centre","startDate":"2018-10-01","conditions":"Trachoma, Yaws, Lymphatic Filariases","enrollment":20000},{"nctId":"NCT01570504","phase":"PHASE3","title":"Multiple Versus Single Dose of Ivermectin for the Treatment of Strongyloidiasis","status":"COMPLETED","sponsor":"Centro per le Malattie Tropicali","startDate":"2013-03","conditions":"Strongyloidiasis","enrollment":312},{"nctId":"NCT01493947","phase":"PHASE3","title":"CD5024 1% [Ivermectin 1%] Cream Versus Metronidazole 0.75% Cream in Papulopustular Rosacea (PPR) Study","status":"COMPLETED","sponsor":"Galderma R&D","startDate":"2012-04","conditions":"Papulopustular Rosacea","enrollment":962},{"nctId":"NCT01903057","phase":"PHASE4","title":"Safety Study of Combined Azithromycin, Ivermectin and Albendazole for Trachoma and Lymphatic Filariasis","status":"WITHDRAWN","sponsor":"Emory University","startDate":"2014-02","conditions":"Trachoma, Lymphatic Filariasis","enrollment":""},{"nctId":"NCT00988533","phase":"PHASE1","title":"A Pharmacokinetics (PK) Study in Lice Infested Children 6 Months to 3 Years of Age","status":"COMPLETED","sponsor":"Topaz Pharmaceuticals Inc","startDate":"2009-09","conditions":"Head Lice","enrollment":30},{"nctId":"NCT01068158","phase":"PHASE3","title":"A Study Comparing the Safety and Efficacy of 0.5% Ivermectin Cream to Placebo in Lice Infested Subjects","status":"COMPLETED","sponsor":"Topaz Pharmaceuticals Inc","startDate":"2010-03","conditions":"Head Lice","enrollment":371},{"nctId":"NCT00994422","phase":"PHASE2","title":"Study Comparing the Safety and Efficacy of 0.5% Ivermectin Cream to Placebo in Lice Infested Subjects","status":"COMPLETED","sponsor":"Topaz Pharmaceuticals Inc","startDate":"2009-10","conditions":"Head Lice","enrollment":264},{"nctId":"NCT01066585","phase":"PHASE3","title":"A Safety and Efficacy Study Comparing 0.5% Ivermectin Cream to a Vehicle Control in Subjects With Head Lice Infestation","status":"COMPLETED","sponsor":"Topaz Pharmaceuticals Inc","startDate":"2010-03","conditions":"Head Lice","enrollment":410},{"nctId":"NCT00817713","phase":"NA","title":"Can Presumptive Anthelminthic Treatment Delay the Progression of HIV in ART-naïve Patients in Rural Africa?","status":"TERMINATED","sponsor":"Swiss Tropical & Public Health Institute","startDate":"2009-01","conditions":"HIV Infections, Helminthiasis","enrollment":295}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":31,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Mectizan"],"phase":"phase_3","status":"active","brandName":"Ivermectin on Day 1","genericName":"Ivermectin on Day 1","companyName":"Lihir Medical Centre","companyId":"lihir-medical-centre","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Ivermectin is a macrocyclic lactone that binds to glutamate-gated chloride channels in parasites, causing paralysis and death. Used for Onchocerciasis (river blindness), Lymphatic filariasis, Strongyloidiasis.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}